Press
Stay informed with our newsroom, your source for company updates, product launches, and industry insights. Journalists can reach the Komodo Health Media team at: [email protected].
By providing your email address, you agree to receive marketing communications from Komodo Health. For more information on how we process personal information, please refer to our published Privacy Notice.
Finance veteran to oversee financial strategy as demand for company’s AI platform accelerates
NEW YORK & SAN FRANCISCO — April 30, 2026 — Komodo Health, the leader in AI-powered healthcare intelligence, today announced the promotion of Paul Thomas to Chief Financial Officer (CFO). In this role, Thomas, who has served as Senior Vice President of Finance and Acting CFO since April 2025, will oversee Komodo’s finance organization and enterprise financial strategy.
The appointment comes as the industry reaches an inflection point, with organizations moving beyond using AI as a productivity layer to building and operationalizing it as a core enterprise capability. Komodo is leading this shift with Marmot™, its AI analytics platform built on the Healthcare Map®, the industry’s most comprehensive view of 330+ million patient journeys. Marmot enables organizations to move from static reporting and delayed insights to real-time, trusted intelligence and accelerate critical decision-making across the product life cycle, from trial design to launch strategy to post-market evidence generation.
As adoption of Marmot increases across healthcare and Life Sciences organizations, the ability to align capital allocation, investment strategy, and long-term platform development is essential to sustaining growth.
“Paul’s expertise has been instrumental in advancing Komodo’s strong financial foundation and positioning us for our next phase of AI-led growth,” said Web Sun, President and Co-Founder, Komodo Health. “As our customers move from treating AI as a productivity tool to embedding it as a core part of how they operate, the discipline and strategic alignment he brings will be essential as we continue to scale.”
Since joining Komodo Health, Thomas has played a central role in strengthening the company’s financial strategy, improving operational rigor and enabling disciplined investment across product innovation and go-to-market expansion. His leadership has helped ensure that Komodo can scale aggressively while continuing to invest in the infrastructure required to support enterprise-grade AI development and deployment.
“Komodo is building the AI-powered intelligence that is fundamentally changing how organizations make decisions,” said Thomas. “My focus is on ensuring we have the financial strategy, systems, and discipline to support that growth while continuing to invest in the platform and capabilities that drive impact for our customers.”
Thomas brings more than 20 years of experience in private and public company finance, strategic planning, and investment research. Prior to Komodo Health, he led Strategic Finance and Investor Relations at Talkdesk and played a key role in taking Sumo Logic public in 2020. He began his career as a semiconductor engineer at Intel Corporation before moving into finance roles at Merrill Lynch, Bank of America, and Goldman Sachs.
About Komodo Health
Komodo Health is on a mission to reduce the global burden of disease by building foundational AI for how Life Sciences and healthcare organizations discover, develop, and deliver life-saving therapies. The company’s healthcare-native AI platform Marmot, powered by its Healthcare Map, eliminates slow, fragmented analyses to accelerate critical healthcare decisions across the product life cycle — from trial design to launch strategy to post-market evidence generation. For more information, visit www.komodohealth.com.
Media Contact
Tate LaCasse
PR Manager
[email protected]
Partnership leverages real-world patient insights and AI to improve screening and advance health equity in communities most impacted by prostate cancer
NEW YORK & SAN FRANCISCO — March 4, 2026 — Komodo Health, the leader in AI-powered healthcare intelligence, today announced a strategic partnership with ZERO Prostate Cancer (ZERO), the nation’s leading prostate cancer advocacy and support organization. Through the partnership, ZERO will leverage Komodo’s healthcare-native AI platform and real-world patient journey insights to support its “Blitz the Barriers” initiative.
Prostate cancer is the second-leading cause of cancer death in American men. In 2026 alone, an estimated 333,830 new cases and 36,320 deaths are expected in the U.S. After years of decline, prostate cancer incidence has risen in recent years as screening patterns have shifted. At the same time, the long-standing decline in the death rate has slowed — trends that underscore the urgent need for improved screening and care.¹
ZERO’s Blitz the Barriers initiative aims to eliminate racial and economic disparities in prostate cancer care and close the survival gap. The program implements community-based, culturally tailored outreach and patient navigation to overcome systemic barriers and deep-rooted mistrust of the healthcare system. Focusing on Black men, veterans, and underserved rural communities, the campaign increases access to prostate cancer screenings through education and direct support, addressing the critical disparities that impact survival outcomes in these populations.
Following its successful launch in Atlanta as the first pilot city in 2025, Blitz the Barriers is expanding to additional communities with significant prostate cancer health disparities, including Baltimore, Washington, D.C., New Orleans, Detroit, and Houston. With the support of Novartis and other partners, the initiative aims to expand resources in these communities and save 100,000 lives by 2035.
“Prostate cancer outcomes are deeply influenced by where patients live, whether they can access timely screening, and how quickly they receive follow-up care,” said Courtney Bugler, CEO, ZERO Prostate Cancer. “By partnering with Komodo, we can rapidly identify where screening gaps exist and where patients are falling through the cracks, allowing us to deploy ZERO’s resources more strategically and break down barriers to care that have cost too many lives.”
Through this partnership, Komodo’s AI platform will give ZERO unprecedented and regulatory-compliant visibility into the journeys of prostate cancer patients and individuals receiving prostate-specific antigen (PSA) screenings and subsequent diagnostic and biomarker testing. Powered by its Healthcare Map®, the industry’s most comprehensive view of over 330 million de-identified patient journeys, Komodo’s AI platform delivers actionable insights in minutes, helping ZERO identify screening gaps, breakdowns in care pathways, and populations facing the greatest barriers to access. These critical insights will also strengthen ZERO’s efforts to inform policy advocacy, community investment, and public health initiatives.
“Patient advocacy organizations are on the front lines of improving health outcomes, and they need AI-powered intelligence built for decision-making in complex regulated settings,” said Miles Ennis, Chief Operating Officer, Komodo Health. “By partnering with ZERO, we’re applying our purpose-built AI and deep oncology expertise to translate insight into action so that patients with prostate cancer receive earlier, more equitable, and more effective care.”
By turning data into a clear roadmap for action, the partnership demonstrates how purpose-built healthcare AI is driving equitable outcomes for patients and communities nationwide.
Reference:
- American Cancer Society. Key Statistics for Prostate Cancer. 2026. www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html
About Komodo Health
Komodo Health is on a mission to reduce the global burden of disease by building foundational AI for how Life Sciences and healthcare organizations discover, develop, and deliver life-saving therapies. The company’s healthcare-native AI platform Marmot, powered by its Healthcare Map®, eliminates slow, fragmented analyses to accelerate critical healthcare decisions across the product life cycle — from trial design to launch strategy to post-market evidence generation. For more information, visit www.komodohealth.com.
About ZERO Prostate Cancer
ZERO Prostate Cancer (ZERO) is on a mission to improve and save lives from prostate cancer through advocacy, education, awareness, and support. Formerly known as the National Prostate Cancer Coalition, ZERO was founded in 1996 to stand up for people impacted by prostate cancer. Today, ZERO serves as the nation’s leading prostate cancer organization, advancing a future where prostate cancer detection is early, support is unwavering, and care is accessible to all. For over 30 years, ZERO has led the way in prostate cancer advocacy, screenings, and partnerships, successfully unlocking funding toward breakthrough discoveries, treatments, and lifesaving access to care.
As the nation’s #1 provider of prostate cancer resources, programs, and services, ZERO has supported millions of people at-risk or diagnosed, and their families. As the voice of the prostate cancer community, ZERO’s urgent focus on breaking barriers to survival — by closing gaps in diagnosis, treatment, and care — brings critical attention to those most likely to be impacted by this disease. Learn more at ZEROcancer.org.
Media Contact
Tate LaCasse
PR Manager
[email protected]
Seasoned AI Platform Leader from Meta to Drive Komodo’s AI-Native Technology Strategy
NEW YORK & SAN FRANCISCO — January 15, 2026 — Komodo Health®, the leader in AI-powered healthcare intelligence, today announced the appointment of Amit Sangani as Chief Technology Officer (CTO). Sangani will lead Komodo’s technology, engineering, and AI platform strategy as the company continues to scale Marmot™, its AI platform designed to help Life Sciences and healthcare organizations innovate faster and improve patient outcomes.
The appointment comes at a pivotal moment for Komodo as demand for AI-powered healthcare intelligence accelerates across the Life Sciences industry. Following the launch of Marmot, Komodo is deepening its investment in AI-native capabilities, requiring technology leadership that can balance architectural rigor with speed, scale, and enterprise-grade execution.
Sangani joins Komodo after 11 years at Meta, where he most recently led teams across the organization and worked with Meta’s Superintelligence Labs on large-scale AI systems. During his tenure, he oversaw core AI platforms including PyTorch and Llama and played a key role in operationalizing AI for enterprise and B2B use cases, helping bring advanced AI systems from research into real-world production at scale. His work focused on building developer-first platforms that enable organizations to more easily access, deploy, and integrate AI.
Prior to Meta, Sangani co-founded and served as CTO of MightyText, scaling the platform to more than 25 million monthly active users, and previously held engineering leadership roles at Google and Composite Software. He brings deep expertise across AI systems, platform engineering, and cloud infrastructure, along with a strong reputation for building high-performing global teams.
“Amit brings the exact combination of technical depth, platform leadership, and execution discipline we need as we double down on our AI-native future,” said Arif Nathoo, CEO and Co-Founder of Komodo Health. “His experience scaling foundational AI platforms and translating complex technology into production-ready systems makes him uniquely suited to lead Marmot’s next phase of growth and impact.”
As CTO, Sangani will be responsible for advancing Komodo’s AI platform architecture, increasing development velocity and accountability, and ensuring Marmot continues to meet enterprise customers where they work through robust APIs and integrations.
“I’m excited to join Komodo at a moment when AI has the potential to meaningfully improve healthcare decision-making,” said Sangani. “Komodo’s mission, data assets, and commitment to responsible AI create a powerful opportunity to deliver real-world impact at scale.”
About Komodo Health
Komodo Health is on a mission to reduce the global burden of disease by building foundational AI for how Life Sciences and healthcare organizations discover, develop, and deliver life-saving therapies. The company’s healthcare-native AI platform Marmot, powered by its Healthcare Map®, eliminates slow, fragmented analyses to accelerate critical healthcare decisions across the product life cycle — from trial design to launch strategy to post-market evidence generation. For more information, visit www.komodohealth.com.
Listing allows AWS customers to easily access and deploy Komodo’s solutions, reducing procurement complexity and driving faster time to value
New York, NY and San Francisco, CA — December 18, 2025 — Komodo Health®, the leader in AI-powered healthcare intelligence, today announced the launch of its availability in AWS Marketplace, providing healthcare and Life Sciences organizations with accelerated access to its healthcare analytics AI platform. Through Komodo’s listings, AWS customers can quickly discover, purchase, and deploy Komodo’s offerings directly within their existing AWS environment — accelerating time to value by eliminating lengthy procurement cycles.
Built on Komodo’s Healthcare Map®, the industry’s most authoritative view of over 330 million de-identified patient journeys, Komodo’s healthcare analytics AI platform Marmot™ is purpose-built for the complexity of healthcare. It enables users to answer their most complex questions by surfacing transparent, verifiable insights in minutes, supporting strategic decision-making across Clinical Development, Commercial, Medical Affairs, and Market Access functions. By listing in AWS Marketplace, Komodo and AWS together are removing a critical barrier to innovation: the slow, resource-intensive procurement cycles.
“At Komodo, we are building a future for healthcare and Life Sciences where better patient outcomes are powered by real-time and verifiable insights,” said Miles Ennis, Chief Operating Officer at Komodo Health. “Our AWS Marketplace listing reduces procurement hurdles, allowing customers to focus on innovation.”
Key benefits of Komodo’s AWS Marketplace listing include:
- Rapid deployment: Accelerate onboarding and implementation directly through AWS Marketplace
- Procurement simplification: Consolidated billing through AWS, with spending eligible toward AWS commitments
- Validated architecture: Komodo’s listing carries the “Reviewed by AWS” badge, ensuring security, compliance, and operational readiness
Komodo’s initial listing is now available in AWS Marketplace, with additional solutions expected to be added in early 2026. To access the listing or learn more, visit https://www.komodohealth.com/contact/.
About Komodo Health
Komodo Health is on a mission to reduce the global burden of disease by building foundational AI for how Life Sciences and healthcare organizations discover, develop, and deliver life-saving therapies. The company’s healthcare-native AI platform Marmot, powered by its Healthcare Map, eliminates slow, fragmented analyses to accelerate critical healthcare decisions across the product life cycle — from trial design to launch strategy to post-market evidence generation. For more information, visit www.komodohealth.com.
Veteran marketing executive from Microsoft, Tableau, and Informatica to lead marketing and scale Komodo’s AI-first strategy
NEW YORK & SAN FRANCISCO — October 22, 2025 — Komodo Health, the leader in AI-powered healthcare intelligence, today announced the appointment of Mark Jewett as Chief Marketing Officer (CMO). Jewett will lead the company’s marketing, shaping brand, communications, and go-to-market strategy as it scales Marmot™ — its new AI platform designed to help Life Sciences and healthcare organizations innovate faster and serve patients better.
The appointment comes following a period of significant momentum for Komodo Health, including the recent launch of Marmot and recognition on the 2025 Forbes Cloud 100 and TIME’s World’s Top HealthTech Companies. As demand for AI-powered healthcare intelligence accelerates across the Life Sciences industry, Komodo is scaling to meet growing customer demand, requiring stronger marketing leadership to expand market awareness and drive platform deployment.
Jewett brings more than 25 years of experience leading marketing teams at major technology companies including Microsoft, Tableau, and Informatica. Throughout his career, he has focused on marketing data and AI solutions — from SQL Server and Azure at Microsoft to data analytics at Tableau and AI-powered data management at Informatica. He has a proven track record of leveraging technology and storytelling to drive growth at scale.
“Mark brings proven marketing leadership to meet the strong demand we’ve received for Marmot, our AI-powered healthcare intelligence platform designed to accelerate healthcare innovation and improve patient outcomes,” said Web Sun, President and Co-Founder of Komodo Health. “His expertise in scaling marketing organizations and translating complex technology into compelling narratives positions him to amplify Komodo’s market leadership as we advance our AI-first vision.”
As CMO, Jewett will oversee all marketing functions, including brand strategy, product marketing, communications, demand generation, and go-to-market execution. He will be responsible for strengthening Komodo’s market leadership and driving awareness of how Marmot is transforming the speed and rigor of critical healthcare decision-making.
“I’m excited to join Komodo at such a transformative moment,” Jewett said. “Komodo is uniquely positioned to help apply AI to reduce the burden of disease. I’ve seen firsthand how the right combination of technology and storytelling can accelerate market adoption.”
About Komodo Health
Komodo Health is on a mission to reduce the global burden of disease by building foundational AI for how Life Sciences and healthcare organizations discover, develop, and deliver life-saving therapies. The company’s healthcare-native AI platform Marmot, powered by its Healthcare Map®, eliminates slow, fragmented analyses to accelerate critical healthcare decisions across the product life cycle — from trial design to launch strategy to post-market evidence generation. For more information, visit www.komodohealth.com.
Media Contacts
Rowena Kelley
858.405.1971
[email protected]
Real Chemistry for Komodo Health
[email protected]
Real-world data shows ADC treatment rates increased 3.7-fold with faster access, yet older women (ages 66+) faced rates 3.4 times lower than younger patients
NEW YORK & SAN FRANCISCO — October 20, 2025 — On the 40th anniversary of Breast Cancer Awareness Month, a new analysis from Komodo Health, the leader in AI-powered healthcare intelligence, conducted in collaboration with the Tigerlily Foundation, a national breast cancer patient advocacy organization, delivers critical insights into antibody-drug conjugate (ADC) treatment patterns in metastatic breast cancer. The study confirms growing clinical acceptance of this innovative therapy but also reveals persistent inequities in access based on age and insurance status.
The analysis of real-world treatment patterns found encouraging signs of progress: ADC treatment rates increased 3.7-fold from 2021 to 2023, rising from 1,353 to 4,965 per 100,000 newly diagnosed metastatic breast cancer patients. Accompanying this rapid adoption, the median time to treatment decreased from 331 to 109 days.
However, an analysis of age and insurance status revealed a disparity: Women age 66 and older had the lowest ADC treatment rates and experienced a median of 242 days to treatment, 3.4 times lower than the treatment rate seen in the youngest cohort, ages 19 to 35.
These findings were uncovered using Komodo’s healthcare-native AI platform, Marmot™, which rapidly analyzes complex care patterns in minutes. Marmot provided the evidentiary-grade insights needed to confirm the momentum of therapeutic innovation while addressing systemic inequities.
“The encouraging patterns we see in this analysis — where ADC utilization aligns with disease biology — suggest that equitable outcomes are possible in precision medicine. Understanding the factors that contributed to these patterns can inform future therapeutic development,” said Maimah Karmo, CEO and Founder, Tigerlily Foundation. “However, the question of why older women have significantly lower treatment rates remains critical and demands investigation to ensure appropriate care for all patients.”
Breakthroughs and Barriers in ADC Access
Leveraging its Healthcare Map®, which tracks the healthcare journeys of over 330 million de-identified U.S. patients, Komodo analyzed treatment patterns among roughly 17,000 women newly diagnosed with metastatic breast cancer who received treatment with three key FDA-approved ADCs — Kadcyla®, Enhertu®, and Trodelvy® — between 2021 and 2023. The analysis revealed additional insights, including:
- Encouraging alignment with disease biology. Despite similar overall metastatic breast cancer incidence rates between White and Black women, ADC usage patterns differed substantially, aligning with known cancer subtypes. Black women had the highest overall ADC treatment rate, primarily driven by Trodelvy® use for triple-negative breast cancer, a subtype more common in this population.¹ Asian women showed higher rates of HER2-targeted ADCs (Enhertu®, Kadcyla®), while White women had lower overall ADC usage, consistent with different breast cancer subtype distributions.
- Access barriers. Medicaid claims showed patients with the highest treatment rates, nearly twice the rate of patients insured by Medicare and higher than commercially insured patients.
The Power of Real-World Intelligence
“Our analysis uncovers a dual reality of precision oncology today: the progress in quickly adopting life-saving therapies like ADCs, coupled with systemic barriers that create disparate access for older patients,” said Tabby Khan, MD, MPH, Senior Director of Analytics, Komodo Health. “By leveraging the speed and precision of Marmot, we were able to not only track progress but also pinpoint these critical gaps to health equity, empowering the entire healthcare ecosystem with the evidentiary view and data needed to understand where policy and practice must be adapted to ensure every patient, regardless of age, benefits from innovative therapeutics.”
Read the full research brief here.
Reference: 1. Siddharth S, Sharma D. Racial Disparity and Triple-Negative Breast Cancer in African-American Women: A Multifaceted Affair between Obesity, Biology, and Socioeconomic Determinants. Cancers. 2018;10(12):514. https://doi.org/10.3390/cancers10120514
About Komodo Health
Komodo Health is the leader in healthcare intelligence, building the foundational AI that is powering the future of how Life Sciences and healthcare organizations discover, develop, and deliver patient care. By deploying Marmot, its proprietary AI engine, across its Healthcare Map, the industry’s most authoritative and highest-fidelity platform for real-world de-identified patient insights, Komodo is ending the era of slow, fragmented analyses. Komodo’s healthcare-native AI platform makes it possible to answer complex questions with the speed and rigor required to accelerate critical decisions across the product life cycle — from trial design to launch strategy to post-market evidence generation — to ultimately reduce the burden of disease. For more information, visit Komodohealth.com.
Media Contacts
Rowena Kelley
858.405.1971
[email protected]
Real Chemistry for Komodo Health
[email protected]
NEW YORK & SAN FRANCISCO – Komodo Health today announced the launch of its Healthcare Map® on Snowflake Marketplace, providing thousands of data-driven organizations with seamless access to the industry’s most comprehensive healthcare intelligence platform.
The Healthcare Map offers the most authoritative and highest-fidelity view into the healthcare journeys of over 330 million de-identified patients. With this integration, Komodo and Snowflake, the AI Data Cloud company, are addressing a critical industry challenge: the difficulty of accessing high-quality, comprehensive, and analytics-ready healthcare data without complex procurement processes and lengthy data engineering cycles.
Through this collaboration, healthcare and Life Sciences customers can now discover and access curated datasets from Komodo’s de-identified healthcare data directly within their existing Snowflake environment. This integration enables data scientists, analysts, and business leaders to accelerate the development of research and commercial strategies, from identifying undiagnosed patients and studying treatment pathways to modeling population health trends.
“Our mission at Komodo is to reduce the global burden of disease by making healthcare intelligence more accessible and impactful,” said Miles Ennis, Chief Operating Officer at Komodo Health. “By listing on Snowflake Marketplace, we’re placing our foundational Healthcare Map directly into the hands of the innovators building the future of healthcare. This removes friction, shortens the time to insight, and empowers our customers to answer their most complex questions with greater speed and confidence.”
Key Benefits of the Komodo Health Offering on Snowflake Marketplace Include:
- Unparalleled Coverage: Access data derived from the journeys of over 330 million de-identified patients across all payer types and settings of care. The Healthcare Map covers de-identified patient journeys in the United States and Canada.
- Privacy-First Data: All data is rigorously de-identified to protect patient privacy and ensure HIPAA compliance. No Protected Health Information (PHI) or Personally Identifiable Information (PII) is ever shared.
- Analytics-Ready Asset: The data is fully integrated and deduplicated, normalized, and enriched for immediate use in machine learning (ML) pipelines, Real-World Evidence (RWE) studies, and Health Economics and Outcomes Research (HEOR).
- Streamlined Access: Available through Capacity Drawdown, eliminating lengthy data procurement cycles with the ability to transact through the Snowflake Marketplace.
“Komodo’s listing on Snowflake Marketplace gives our joint customers access to industry-leading healthcare intelligence within their existing workflows — no data movement required,” said Jesse Cugliotta, Global Head of Healthcare & Life Sciences at Snowflake. “This depth of real-world, de-identified patient journey data enables healthcare and Life Sciences organizations to build more sophisticated analytical models and accelerate insights that ultimately improve patient outcomes.”
Access Komodo’s listing on Snowflake Marketplace here.
About Komodo Health
Komodo Health is on a mission to reduce the global burden of disease by building foundational AI for how Life Sciences and healthcare organizations discover, develop, and deliver life-saving therapies. The company’s healthcare-native AI engine Marmot™, powered by the Healthcare Map, eliminates slow, fragmented analyses to accelerate critical healthcare decisions across the product life cycle. For more information, visit www.komodohealth.com.
Media Contacts
Rowena Kelley
858.405.1971
[email protected]
Real Chemistry for Komodo Health
[email protected]
Triple recognition validates company’s pioneering healthcare-native AI approach and accelerated market leadership
NEW YORK & SAN FRANCISCO — September 30, 2025 — Komodo Health, the leader in AI-powered healthcare intelligence, today announced that it has earned recognition on three prestigious industry lists: the 2025 Forbes Cloud 100, TIME’s inaugural World’s Top HealthTech Companies, and The Healthcare Technology Report’s Top 25 Healthcare Software Companies. These honors validate Komodo’s differentiated approach to healthcare analytics AI — purpose-built from the ground up rather than retrofitted from consumer applications — and arrive during a milestone year of unprecedented growth and innovation.
Breakthrough AI Innovation Drives Market Leadership
The recognition comes as Komodo accelerates its market leadership through breakthrough AI innovation. The company recently launched Marmot™, the industry’s first healthcare-native AI engine, which fundamentally transforms how organizations generate insights from healthcare data. Unlike foundational AI models adapted for healthcare use, Marmot was engineered specifically for healthcare and Life Sciences workflows with deep domain expertise, advanced analytics, and healthcare-specific reasoning capabilities.
Built on Komodo’s Healthcare Map®, which captures insights from over 330 million de-identified U.S. patients, Marmot delivers transparent, verifiable insights in minutes rather than weeks, enabling critical decisions across the entire product life cycle, from clinical trial design to post-market evidence generation.
Expanding Impact Across Healthcare and Beyond
Komodo’s influence extends well beyond traditional healthcare boundaries. The company powered more than 250 peer-reviewed studies and 31 presentations at ISPOR 2025, demonstrating the scientific rigor and real-world impact of its healthcare analytics AI platform. Additionally, Komodo is advancing healthcare insights for Financial Services through a groundbreaking partnership with Nasdaq while broadening strategic alliances with leading technology innovators, including Databricks and Snowflake.
“These recognitions reflect our team’s dedication to building healthcare analytics AI the right way — leveraging decades of domain expertise and 11 years of executing on our full stack thesis, spanning our Healthcare Map, platform capabilities, and healthcare analytics AI,” said Web Sun, President and Co-Founder, Komodo Health. “Marmot validates our core thesis: When AI is purpose-built for healthcare workflows rather than retrofitted from consumer applications, teams get the speed and transparency they need to drive their business and improve patient outcomes with confidence.”
Industry Validation for Purpose-Built AI
The Forbes Cloud 100, which Komodo has been recognized on five times, represents the definitive ranking of the top 100 private cloud companies globally. TIME’s World’s Top HealthTech Companies highlights companies that deliver the most impactful health technologies. Komodo earned specific recognition in the AI & Data Analytics category with an “Outstanding” performance indicator. The Healthcare Technology Report honors healthcare software companies that are defining the future of healthcare delivery through advanced analytics and AI-driven solutions.
Together, these recognitions underscore Komodo’s market-defining approach, as the healthcare industry increasingly demands solutions that balance rapid insights with strict regulatory compliance. Marmot’s healthcare-native design uniquely delivers the analytical rigor and transparency that critical decisions require and positions Komodo to set the industry standard for trustworthy, high-impact insights.
About Komodo Health
Komodo Health is on a mission to reduce the global burden of disease by building foundational AI for how Life Sciences and healthcare organizations discover, develop, and deliver life-saving therapies. The company’s healthcare-native AI engine Marmot, powered by the Healthcare Map, eliminates slow, fragmented analyses to accelerate critical healthcare decisions across the product life cycle. For more information, visit www.komodohealth.com.
Media Contacts
Rowena Kelley
858.405.1971
[email protected]
Real Chemistry for Komodo Health
[email protected]
Analysis from Komodo Health and Medscape Education shows cognitive screening up 10% and biomarker testing up 23%, yet significant disparities persist in detection for women and treatment access for Black patients
NEW YORK & SAN FRANCISCO – September 18, 2025 – New research from Komodo Health and Medscape Education reveals both progress and persistent challenges in Alzheimer’s disease care: Breakthrough therapies and targeted medical education are driving significant increases in early detection — with cognitive screening rising 10%, biomarker testing up 23%, and amyloid pathology testing surging more than 13-fold. However, patients at the highest risk are receiving treatments at the lowest rates. The analysis found that women are still screened at rates similar to men despite accounting for 64% of Alzheimer’s diagnoses. Additionally, Black patients, who made up 10% of Alzheimer’s patients, accounted for only 3% of those treated with the new therapy.
With Alzheimer’s cases projected to nearly double from 7.2 million Americans today to over 13 million by 2060¹, understanding current treatment gaps has never been more critical. This new analysis, released ahead of World Alzheimer’s Day on September 21, provides timely insights into patient screening and treatment patterns following the FDA’s groundbreaking 2023 approval of lecanemab, the first anti-amyloid therapy shown to slow Alzheimer’s progression. Using Komodo’s healthcare-native AI analytics engine Marmot™, researchers leveraged Komodo’s Healthcare Map®, which captures the healthcare journeys of over 330 million de-identified patients, and Medscape Education’s proprietary platform, PULSE, to rapidly analyze complex care patterns that would typically require months of traditional research. The analysis reveals how innovation is reshaping the Alzheimer’s landscape and where critical gaps persist.
Treatment Disparities Persist Despite Progress in Screening
The analysis confirmed a positive trend in early detection, identifying the disease in its subclinical or preclinical stages, with cognitive screening rising 10%, gene and protein biomarker testing increasing 23%, and amyloid pathology testing surging more than 13-fold in the 18 months post-approval. However, this progress is not distributed equitably across all populations, as evidenced by the following:
- Screening disparities persist. While women make up 64% of Alzheimer’s diagnoses, they are screened at similar rates as men. Black individuals were screened at a similar rate as White individuals despite having a higher diagnosis rate
- Treatment gaps are notable. Despite comprising 10% of the Alzheimer’s patient population, Black patients accounted for only 3% of those treated with lecanemab. The treatment rate for Black patients was more than four times lower than that of White patients
- Insurance status and age present barriers. Despite representing only 3.7% of the Alzheimer’s population, commercially insured patients were treated at rates more than three times higher than Medicare patients and 17 times higher than Medicaid patients. Similarly, while 82% of Alzheimer’s cases occur in patients age 75 and older, this group had a much lower treatment rate with the second approved disease-modifying therapy, far below patients ages 55 to 64, who saw the highest treatment rates
“These findings demonstrate both the opportunity as well as the urgent work still required,” said Arif Nathoo, MD, Co-Founder and CEO, Komodo Health. “While we’re seeing meaningful progress in early detection, we’ve also surfaced inequities in treatment access that should be addressed today so we can shape a better future for the millions of Americans projected to suffer from Alzheimer’s in the coming years. By using our healthcare-native analytics AI to identify these disparities in minutes rather than weeks, we’re empowering our partners across the healthcare ecosystem with the evidence they need to build on the detection advances and address access gaps — ensuring every patient benefits from these life-changing therapies.”
The Importance of Education in Shifting Treatment Patterns
The analysis also underscores the need for continuous innovation in Alzheimer’s treatment and the importance of clinical education in improving treatment delivery.
“It’s often thought that continuing medical education programs don’t change clinical practice. This study provides evidence that, when properly timed, these programs can have substantial effects on physician engagement and action on the detection and diagnosis of Alzheimer’s,” said Dr. Soo Borson, Deputy Editor, Journal of the American Geriatrics Society and Co-Lead, BOLD Center of Excellence on Early Detection of Dementia.
The analysis found that a wide spectrum of healthcare professionals, including nurse practitioners and physician assistants, are prescribing lecanemab. Specifically, these providers accounted for 40% of prescriptions, nearly matching neurologists and psychiatry specialists, who accounted for 42%. Following the approval of new therapies, clinicians involved in Alzheimer’s care consumed 18% more independent medical education content through Medscape Education, leading to a 19% rise in their confidence in Alzheimer’s-related practices.
“Our research shows a powerful link between timely medical education and positive change in mechanisms that are associated with clinical practice,” said Katie Lucero, PhD, Chief Impact Officer, Medscape Education. “Equipping clinicians with the latest knowledge and increasing their confidence are essential to ensuring that all patients benefit from these advances.”
To learn more, download the full research brief here.
About Komodo Health
Komodo Health is the leader in healthcare intelligence, building the foundational AI that is powering the future of how Life Sciences and healthcare organizations discover, develop, and deliver patient care. By deploying Marmot, its proprietary AI engine, across its Healthcare Map, the industry’s most authoritative and highest-fidelity platform for real-world de-identified patient insights, Komodo is ending the era of slow, fragmented analyses. Komodo’s healthcare-native AI platform makes it possible to answer complex questions with the speed and rigor required to accelerate critical decisions across the product life cycle — from trial design to launch strategy to post-market evidence generation — to ultimately reduce the burden of disease. For more information, visit www.komodohealth.com.
About Medscape Education
Medscape Education (Medscape.org) is the leading destination for continuous professional development, consisting of more than 30 specialty-focused destinations offering thousands of free accredited courses for physicians, nurses, and other healthcare professionals. Medscape Education is a part of WebMD Health Corp., an Internet Brands company.
- 2025 Alzheimer’s disease facts and figures. Alzheimer’s & Dementia. 2025:21(4); e70235. doi: https://doi.org/10.1002/alz.70235
Media Contacts:
Komodo Health
Rowena Kelley
858.405.1971
[email protected]
Real Chemistry for Komodo Health
[email protected]
Medscape Education
Jaberta Bennett
404.660.7002
[email protected]
Technology veteran to scale operations as AI healthcare analytics platform accelerates market expansion
SAN FRANCISCO, CA — September 4, 2025 — Komodo Health, the leader in AI-powered healthcare intelligence, today announced the appointment of Miles Ennis to Chief Operating Officer (COO). Ennis, who joined Komodo Health as Chief Revenue Officer in July 2024, will expand his leadership role to oversee the company’s operational strategy and execution across all business functions while continuing to drive commercial excellence.
The announcement comes as Komodo Health scales to meet intense demand for its breakthrough AI innovations such as Marmot™ — its proprietary AI engine that empowers Life Sciences organizations to answer complex questions with unprecedented speed and rigor — which require enhanced operational capabilities to support rapid market expansion and platform deployment across enterprise customers.
Since joining Komodo, Ennis has been a driving force behind the company’s success, leading the revenue organization to consistently exceed commercial objectives while building strategic partnerships that have expanded Komodo’s market reach. His commercial leadership has established a groundbreaking partnership with Nasdaq that has brought healthcare intelligence to the Financial Services industry for the first time. This partnership enables hedge fund, private equity, and venture capital firms to make more informed investment decisions with insights from Komodo’s Healthcare Map®, which tracks the healthcare journeys of 330+ million patients in the U.S.
“Miles’s impact has been profound and immediate,” said Web Sun, President and Co-Founder of Komodo Health. “In his time as CRO, he has not only delivered outstanding commercial results, he has also demonstrated the strategic vision and operational rigor that has elevated our organization. His promotion to COO is a natural progression that positions him to scale our operations and deliver unparalleled value to our customers.”
As COO, Ennis will lead company-wide operations spanning Revenue, Services, Account Management, Customer Success, Consulting, and Strategic Programs while driving improved cross-functional execution across Product Engineering, Marketing, and Technology. He will be responsible for aligning Komodo’s people, processes, and platforms to accelerate growth, scale delivery, and strengthen the company’s position as a market leader in healthcare analytics AI.
“I’m honored to take on this expanded role at such an exciting time in Komodo’s evolution,” Ennis said. “My focus will be on building the operational infrastructure needed to scale our AI platform across global markets while maintaining the speed and precision our customers expect. As we accelerate Marmot deployment and expand into new market segments, operational excellence is even more critical to delivering on our mission of reducing disease burden.”
Ennis brings more than 20 years of experience in scaling global teams and driving digital transformation at major technology companies, including Talkdesk, IBM, Cisco, and Aspen Technology. His expertise in complex commercial operations and strategic growth has been instrumental in Komodo’s continued market expansion.
About Komodo Health
Komodo Health is the leader in healthcare intelligence, building the foundational AI that is powering the future of how Life Sciences and healthcare organizations discover, develop, and deliver patient care. By deploying Marmot, its proprietary AI engine, across its Healthcare Map, the industry’s most authoritative and highest-fidelity platform for real-world de-identified patient insights, Komodo is ending the era of slow, fragmented analyses. Komodo’s healthcare-native AI platform makes it possible to answer complex questions with the speed and rigor required to accelerate critical decisions across the product life cycle — from trial design to launch strategy to post-market evidence generation — to ultimately reduce the burden of disease. For more information, visit www.komodohealth.com.
Media Contacts:
Rowena Kelley
858.405.1971
[email protected]
Taylor Hall
305.742.6458
[email protected]
Purpose-built healthcare analytics AI delivers on-demand intelligence to unlock new opportunities for patient care advancement
NEW YORK, NY and SAN FRANCISCO, CA— August 20, 2025 — Komodo Health, the leader in AI-powered healthcare intelligence, today launched Marmot™, the first healthcare-native AI engine built to serve as the foundational intelligence layer for the discovery, development, and delivery of patient care. Marmot generates transparent, verifiable healthcare analytics in minutes, empowering Life Sciences and healthcare teams to innovate at the speed of thought and accelerate the delivery of life-saving therapies.
In an industry where AI is projected to unlock an $868 billion healthcare opportunity by 2030,¹ organizations need purpose-built solutions that can keep pace with the speed of scientific discovery and help navigate the complexities of precision medicine. Built on the principle that AI should amplify rather than replace human expertise, Marmot is where your healthcare expertise meets AI.
“In a highly competitive environment, speed to insight is a critical differentiator,” said Arif Nathoo, MD, CEO and Co-Founder, Komodo Health. “Built on our Healthcare Map with healthcare reasoning and pharmaceutical domain expertise engineered directly into the AI, Marmot fundamentally enhances analytical velocity, transforming complex questions that previously took weeks to answer into strategic, evidence-based insights in minutes. By designing Marmot to handle the complex analytical work, we’re creating space for Life Sciences teams to focus on strategic decisions that bring therapies to patients faster.”
This vision is already becoming reality. Building on an existing five-year strategic partnership, Alnylam Pharmaceuticals has entered into an enterprise agreement to embed Marmot into its operations. The collaboration will focus initially on deploying custom AI agents for Alnylam’s key business functions.
Purpose-Built for Healthcare Excellence
Unlike generic AI models that may be retrofitted for healthcare, Marmot is purpose-built on Komodo’s Healthcare Map®, the industry’s most authoritative and highest-fidelity view into the healthcare journeys of over 330 million de-identified patients. Drawing on a knowledge graph built from millions of prior analyses, Marmot delivers enterprise-ready AI that understands the unique requirements of regulated healthcare environments from day one.
Marmot advantages include:
- AI that speaks Healthcare: Marmot’s healthcare-native reasoning and built-in, battle-tested analytics methods — refined through millions of prior analyses — enable immediate deployment and consistent results, eliminating the risks of generic AI
- Verifiable, trustworthy insights: Every insight is accompanied by auditable code and scrutinized by an independent review agent that mirrors a scientific peer-review process, addressing the critical trust gap that has limited AI adoption
- Analytics at the speed of thought: Moving from weeks to minutes-fast analytics creates immediate competitive advantages, from accelerating time to market to testing multiple therapeutic strategies in parallel
- Expert empowerment: Designed to amplify — not replace — human expertise, Marmot handles complex data integration and coding, freeing teams to focus on the high-impact strategic thinking that improves patient outcomes
“Marmot demonstrates what’s possible when AI is built specifically for pharmaceutical insights workflows rather than retrofitted from generic consumer applications,” said Web Sun, President and Co-Founder, Komodo Health. “By integrating seamlessly across Commercial and Medical Affairs operations while meeting the rigorous transparency and auditability standards that regulated industries require, Marmot doesn’t just deliver faster analytics, it gives Life Sciences teams the confidence to act on AI-generated insights.”
Availability
Marmot is now available to healthcare and Life Sciences organizations. Join the launch webinar tomorrow, August 21, at 2 p.m. ET with Arif Nathoo and Web Sun to see Marmot in action. For more information about Marmot, click here.
About Komodo Health
Komodo Health is the leader in healthcare intelligence, building the foundational AI that is powering the future of how Life Sciences and healthcare organizations discover, develop, and deliver patient care. By deploying Marmot, its proprietary AI engine, across its Healthcare Map, the industry’s most authoritative and highest-fidelity platform for real-world de-identified patient insights, Komodo is ending the era of slow, fragmented analyses. Komodo’s healthcare-native AI platform makes it possible to answer complex questions with the speed and rigor required to accelerate critical decisions across the product life cycle — from trial design to launch strategy to post-market evidence generation — to ultimately reduce the burden of disease. For more information, visit www.komodohealth.com.
Media Contacts:
Rowena Kelley
858.405.1971
[email protected]
Taylor Hall
305.742.6458
[email protected]
- Dizinger J, Müller J, Ahrens F, et al. AI’s US$ 868 billion healthcare revolution. Strategy&. 2025.
Anervea to Build Breakthrough ClinDev Optimization Suite on Komodo’s MapLab Enterprise, Harnessing Real-World Data and AI to Accelerate Market Access and Improve Patient Outcomes
SAN FRANCISCO, CA – July 23, 2025 – Komodo Health, the Evidentiary Standard for real-world patient-journey insights and healthcare analytics, today announced a strategic partnership with Anervea.ai, an AI-native Life Sciences technology company, to accelerate innovation across Clinical Development. Among the top biopharma companies, the average investment required to shepherd a single medicine from discovery through regulatory approval hovers around $2.2 billion,¹ yet less than 1 in 10 candidates that enter human testing ever reach the U.S. market.² Together, Komodo and Anervea aim to solve that.
Through this partnership, Anervea will develop and deploy an AI-powered suite of applications on Komodo’s MapLab Enterprise™ platform, leveraging Komodo’s real-time, longitudinal Healthcare Map® to enhance key stages of clinical research and trial execution and enable Life Sciences teams to accelerate data-driven clinical development through AI-powered healthcare intelligence.
Life Sciences organizations that deploy the Anervea.ai solution through MapLab Enterprise can expect to accelerate strategic intelligence across the development life cycle, including:
- Predictive modeling of clinical trial success across protocol variants and geographies
- Early forecasting of market success based on real-world adoption and referral patterns
- Simulation of launch pricing and reimbursement scenarios using analogs and payer data
- Real-time insights to inform regulatory strategy, trial feasibility, and portfolio risk
- Intelligent recommendations on protocol design, site selection, and diversity optimization
By embedding these capabilities within Komodo’s healthcare intelligence platform, Anervea will deliver a new generation of AI tools that drive faster, more informed decisions — from molecule to market.
“Komodo’s Healthcare Map gives us the depth, scale, and reliability needed to bring real-world intelligence to the heart of clinical development,” said Ayush Atul Mishra, Founder and CEO of Anervea.ai. “Our vision is to help clinical and R&D teams move with speed and precision by embedding AI into the workflows that matter most — from trial design to execution. This partnership marks a major step toward that goal.”
The partnership underscores Komodo’s commitment to delivering AI-enabled insights that empower healthcare and Life Sciences to improve patient outcomes. Anervea will be the first partner in Komodo’s ecosystem to build licensable, AI-native tools directly on top of Komodo’s trusted healthcare intelligence platform. This strategy enables technology partners to focus on cutting-edge product development while leveraging Komodo’s scalable infrastructure, regulatory-grade data-driven insights, and enterprise deployment framework.
“This collaboration exemplifies Komodo Health’s strategic commitment to democratizing and expanding the impact of our industry-leading healthcare insights through partnerships with groundbreaking technology innovators like Anervea.ai,” said Miles Ennis, Chief Revenue Officer, Komodo Health. “By enabling Anervea.ai to build its powerful AI-native tools directly on our trusted MapLab Enterprise platform, we are empowering Life Sciences organizations to not only make more informed decisions, but fundamentally accelerate and optimize clinical trial design and execution, ultimately benefiting patients.“
The application suite will be available to Life Sciences companies as both a stand-alone web-based solution and an embedded experience within the MapLab platform, providing flexible integration for sponsors and CROs.
About Komodo Health
Komodo is a healthcare insights and technology company that delivers the Evidentiary Standard for real-world data and analytics. By pairing the industry’s most complete, unbiased view of patient encounters with AI-enabled and fit-for-purpose software, Komodo connects the dots between patient journeys and large-scale health outcomes. Across Life Sciences, payers, providers, and developers, Komodo delivers a velocity advantage by helping its customers accurately and efficiently access patient-centric insights at scale to drive faster decision-making, optimize workflows, close gaps in care, and help reduce the burden of disease. For more information, visit Komodohealth.com.
About Anervea.ai
Anervea.ai is building the next generation of AI-native applications to power strategic decisions in pharma. Its predictive analytics platform and clinical intelligence tools help life sciences organizations optimize development timelines, trial outcomes, and market strategy. For more, visit anervea.ai.
Media Contacts
Komodo Health
Rowena Kelley
858.255.1651
[email protected]
¹ https://www.deloitte.com/us/en/Industries/life-sciences-health-care/articles/measuring-return-from-pharmaceutical-innovation.html
² https://www.cbo.gov/publication/57126